Productivity Improvement And Restructuring Initiatives (Tables)

12 Months Ended

Dec. 31, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs

Productivity improvement and restructuring related charges, including those related to the discontinuation of the molecular diagnostics product line, recorded for the years ended December 31 by segment were as follows ($ in millions):

	2018		2017		2016
Life Sciences	$	11.4	$	25.4	$	40.5
Diagnostics	14.9		85.4		62.2
Dental	23.7		35.8		34.3
Environmental & Applied Solutions	20.0		12.5		15.4
Total	$	70.0	$	159.1	$	152.4

The table below summarizes the Company’s accrual balance and utilization by type of productivity improvement and restructuring costs associated with the 2018 and 2017 actions ($ in millions):

	Employee Severance & Related			Facility Exit & Related			Total
Balance, January 1, 2017	$	45.3		$	11.8		$	57.1
Costs incurred	77.7			81.4			159.1
Paid/settled	(74.0		)	(75.9		)	(149.9		)
Balance, December 31, 2017	49.0			17.3			66.3
Costs incurred	59.4			10.6			70.0
Paid/settled	(68.8		)	(20.3		)	(89.1		)
Balance, December 31, 2018	$	39.6		$	7.6		$	47.2

Schedule of Restructuring Reserve by Type of Cost

These charges are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):

	2018		2017		2016
Cost of sales	$	16.8	$	38.0	$	25.4
Selling, general and administrative expenses	53.2		121.1		127.0
Total	$	70.0	$	159.1	$	152.4